GD2-Targeted Immunotherapy and Radioimmunotherapy☆,☆☆
Section snippets
Murine Antibodies: IgG3 Antibody 3F8
In the first-in-human phase I study of anti-GD2 monoclonal antibody (MAb), toxicity of murine IgG3 antibody 3F8 was assessed in 17 patients with neuroblastoma and malignant melanoma (Table 1).24 Tumor response by using International Neuroblastoma Response Criteria (INRC)25 was observed in two of 17 patients with neuroblastoma.26 Importantly, this study demonstrated specific binding of 3F8 antibodies to tumor using in vitro immunostaining and in vivo radioimaging with 131I-3F8. Toxicities
Gd2 Vaccines
Building on the success of anti-GD2 antibodies, active vaccination against GD2 is a logical next step.60 HAMA, an indirect measure of the host anti-idiotype network, was consistently correlated with long term survival.34, 60 Because of these observations, anti-idiotypic antibody vaccines such as mouse IgG1 antibody 1A7 specific for ch14.1861 and rat IgG1 antibody A1G4 specific for 3F862 were tested in phase I trials (NCT00003023). The GD2 peptide mimotope63 and its DNA vaccine64 can induce
Immunocytokines
Fusion of cytokines to GD2-specific antibody has the potential to improve tumor delivery and help achieve a higher local concentration and reduce systemic toxicity of the cytokines. In phase I study of hu14.18/IL-2 immunocytokine in 28 children with refractory neuroblastoma and melanoma, no objective responses were observed. DLTs included hypersensitivity, hypotension, and myelosuppression.67 Phase II study included 39 children with refractory neuroblastoma. Of 13 patients with measurable
Importance of NK Cells and the Role of Inhibitory Killer Cell Immunoglobulin-Like Receptor
Anti-GD2 MAb is more than a passive linker of tumors to NK cells; they rescue NK cells from suppression by neuroblastoma. FcγRIII (CD16)-mediated signaling removes the inhibition by inhibitory killer cell immunoglobulin-like receptors (KIRs).74 Since 60% of patients have KIRs on their NK cells with no corresponding KIR ligands during cellular maturation,75 these NK cells are “uneducated” and hyporeactive until their CD16 is activated during ADCC. On the other hand, while “educated” NK cells are
Antibody Drug Conjugates
Antibody immunoconjugates can selectively deliver the cytotoxic payload to the tumor.97 Such conjugates could be a drug (antibody drug conjugates [ADCs]) with known anti-tumor activity, a radionuclide, or a toxin. There are several factors that can affect clinical use of immunoconjugates negatively. The conjugation chemistry can damage immunoreactivity, interfering with antibody binding to the target. Instability of the conjugate in serum can diminish its effect on the target sometimes
Radionuclide Immunoconjugates For Radioimmunotherapy
Radionuclides can exert anti-tumor effect not just on antigen(+) but also on surrounding antigen(-) tumor cells via a “cross-fire” effect and radiation-induced intercellular signaling.99
Choice of Radioisotope and Immunoreactivity
Most clinical applications of RIT utilize β-emitting radioimmunoconjugates. β-particles have a relatively long range (0.8–5 mm) and low linear energy transfer (approximately 0.2 keV/µm). This long range results in the delivery of radiation not only to the antigen-positive, but also to antigen-negative tumor cells, as well as to the surrounding normal tissues. Thus, β-emitters can treat bulky diseases effectively, but they are not optimal for eradicating single cells or micrometastasis. Most
Nanoparticles
Inorganic nanoparticles are delivery systems built to precise specifications for medical applications.98 They represent small particles (3–200 nm) made up of inert scaffolds. As therapeutics, they are built for their superior pharmacokinetics, thereby enhancing intracellular concentration of drugs in cancer cells while minimizing their systemic side effects. In neuroblastoma-bearing mice, fenretinide, a synthetic retinoic acid derivative,114 or doxorubin115 could be encapsulated in
Future Directions
Anti-GD2 antibodies have been extensively evaluated in preclinical and clinical studies in the past two decades. Therapeutic efficacy and acceptable safety profile have made them an integral part of the current treatment of neuroblastoma. Curing high-risk metastatic neuroblastoma diagnosed≥18 months of age or with MYCN amplification was unthinkable 25 years ago. The addition of GD2-targeted treatments has greatly improved their outlook, where>50% PFS beyond 5 years is now possible. Several key
Acknowledgments
The authors thank Drs Irene Cheung, Brian H. Kushner, Kim Kramer, and Shakeel Modak for their critical review of the manuscript and valuable suggestions.
References (135)
- et al.
Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs
Blood
(2007) - et al.
VCN-releasable sialic acid and gangliosides in human neuroblastomas
J Pediatr Surg
(1977) Neuroblastoma
Semin Pediatr Surg
(2012)- et al.
GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma
Blood
(1989) - et al.
Detecting minimal residual disease in neuroblastoma patients-the present state of the art
Cancer Lett
(2005) - et al.
A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma
Eur J Cancer
(1995) - et al.
Systematic amino acid substitutions improved efficiency of GD2-peptide mimotope vaccination against neuroblastoma
Eur J Cancer
(2009) - et al.
Interleukin-15 biology and its therapeutic implications in cancer
Trends Pharmacol Sci
(2012) - et al.
Antidisialo- ganglioside/granulocyte macrophage-colony-stimula- ting factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis
Blood
(2002) - et al.
Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity
Blood
(1992)
Therapeutic intervention with complement and beta-glucan in cancer
Immunopharmacology
Safety and immunologic effects of IL-15 administration in nonhuman primates
Blood
Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins
J Biol Chem
Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion
Anal Biochem
One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody
Blood
Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy
FEBS Lett
Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells
ASN Neuro
Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis
J Clin Invest
Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells
Proc Natl Acad Sci U S A
Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas—an immunohistochemical study
Int J Oncol
Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
J Cell Biol
In silico driven redesign of a clinically relevant antibody for the treatment of gd2 positive tumors
PLoS One
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research
Clin Cancer Res
Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography
Int J Cancer
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas
Cancer
Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma
Cancer Res
Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor
Med Pediatr Oncol
Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial
Eur J Nucl Med
Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells
Cancer Res
Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth
Cancer Res
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
N Engl J Med
Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
Oncoimmunology
Phase I study of anti-GD2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) in patients with relapsed or refractory neuroblastoma (NB) or other GD2-positive solid tumors. Advances in Neuroblastoma Research 2014
Cologne
Phase I study of anti-GD2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with relapsed high-risk neuroblastoma (HR-NB). Advances in Neuroblastoma Research 2014
Cologne
Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor
J Clin Oncol
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
J Clin Invest
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma
J Clin Oncol
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma
J Clin Oncol
Reassessment of patient response to monoclonal antibody 3F8
J Clin Oncol
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study
J Clin Oncol
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age
J Clin Oncol
Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma
J Clin Oncol
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor
J Clin Oncol
Key role for myeloid cells: phase II results of anti-G antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma
Int J Cancer
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission
J Clin Oncol
Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies
Cancer Immunol Immunother
Anti-GD2 antibody 3F8 and barley-derived (1 -->3),(1 -->4)-beta--glucan: a phase I study in patients with chemoresistant neuroblastoma
Oncoimmunology
Phase I study of the combination of anti-GD2 antibody 3F8 and yeast-derived (1 3), 1 6)-β-D-glucan for resistant neuroblastoma
American Society of Pediatric Hematology/Oncology (22nd)
Phase I study of haploidentical natural killer (NK) cells plus monoclonal antibody 3F8 for resistant high-risk neuroblastom (HR-NB). Advances in Neuroblastoma Research 2014
Cologne
Cited by (0)
- ☆
Supported in part by grants from the Department of Defense (PR111043), the National Cancer Institute (CA106450 and CA161978), Enid A Haupt Endowed Chair, Kids Walk for Kids with Cancer NYC, Katie’s Find a Cure Foundation, Catie Hoch Foundation and the Robert Steel Foundation.
- ☆☆
Financial disclosure: N.-K. Cheung was named as an inventor on patents filed by MSKCC on beta-glucan, hu3F8 and 8H9. Beta-glucan was licensed by MSKCC to Biotec Pharmacon.